Opinion

Video

Sequencing Considerations in Relapsed/Refractory CLL

Author(s):

Callie Coombs, MD ,Matthew Davids, MD, MMSc

Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment options in the relapsed/refractory setting.

Video content above is prompted by the following:

  • What sequencing considerations influence your choice of upfront therapy for chronic lymphocytic leukemia (CLL), and how do these decisions shape the selection of treatments in the relapsed/refractoryCLL setting?
  • How does the treatment sequencing study in CLL/SLL by Rhodes and colleagues, presented at the 2024 American Society of Hematology annual meeting, influence your clinical approach?

Related Videos
1 expert is featured in this series.
5 experts are featured in this series.
Related Content
Waist circumference measurement | Image credit: thatinchan - stock.adobe.com
January 21st 2025

Obesity Metrics May Better Reflect CRC Link Than BMI

Pearl Steinzor
Waist circumference and waist-to-hip ratio show stronger links to colorectal cancer (CRC) than body mass index (BMI), a new study has found.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
First-line treatment for MDS often includes hypomethylating agents, so it is common for patients with sAML to have prior exposure to these agents. - Eleni - stock.adobe.com
January 18th 2025

Unmet Needs Remain in Secondary AML Following Treatment With HMAs

Rose McNulty
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
In Charleston, West Virginia, Tracking MPN Symptoms Becomes a Priority
January 17th 2025

In Charleston, West Virginia, Tracking MPN Symptoms Becomes a Priority

Mary Caffrey
Charleston Area Medical Center (AMC) Vandalia Health was among 3 participants in the Association of Cancer Care Centers' Quality Improvement Program for myeloproliferative neoplasms.
AJMC
January 17th 2025

Physiologic Insulin Resensitization Lowers Cost in Patients With Diabetes and Kidney Disease

Zachary Villaverde, BS Roy H. Hinman II, MD Richard M. Grimes, PhD
Patients with diabetes and chronic kidney disease receiving physiologic insulin resensitization had much lower annual costs of care than similar patients not receiving it.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo